Thermi was founded in 2012 in Dallas, Texas and moved to Austin after the company was acquired by Celling Biosciences in 2019, to take advantage of Celling’s multi-million dollar laboratory and headquarters situated within the city’s fast paced bio-tech industry and located on historic South Congress (SoCo). Celling Biosciences produces top of the line innovative biologics solutions, and alongside Thermi’s radio frequency technology, seeks to amplify the delivery of biologics and enhance integrated restorative wellness solutions for our partners across medical specialties. The merging of the Thermi product line with the cutting-edge technology of Celling Biosciences, will fast track the evolution of micro-invasive, preventive and regenerative treatments across the healthcare spectrum.
Celling Biosciences is a pioneer in the science, research and development of autologous cell therapy technology. Celling products are designed to collect, process and deliver autologous cells to the patient at the point of care to accelerate the body’s natural healing process. The Autologous Regenerative Therapies family of concentration systems recovers a high percentage of nucleated, progenitor and other cells by allowing selection of the cell concentrate from user-defined portions of a centrifuged stack. The proprietary system also features an integrated filter for the ultrafiltration of proteins from bone marrow or peripheral blood. For more information, please visit www.cellingbiosciences.com
Thermi’s flagship product is the ThermiRF®, a Radio Frequency platform technology that utilizes proprietary temperature-controlled algorithms for various non-invasive and minimally-invasive applications, such as ThermiTight®, ThermiSmooth® and ThermiVa®. Thermi also recently launched the state of the art ThermiRF+™ device that not only offers a completely re-designed temperature-controlled algorithm but 20W and 50W functionalities. The platform will also offer expanded treatment area options with the release of Thermi’s newest hand pieces (coming Q1 2023).